切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2018, Vol. 12 ›› Issue (06) : 370 -372. doi: 10.3877/cma.j.issn.1674-0807.2018.06.010

所属专题: 文献

讲座

基于人群的乳腺癌预后参数研究现状
陈莉莉1, 石菊芳2,(), 刘玉琴1,(), 岳馨培2, 王乐2, 马恒敏3, 黄慧瑶2, 王仲照4, 代敏2   
  1. 1. 730050 兰州,甘肃省肿瘤医院肿瘤流行病学研究中心
    2. 100021 北京,中国医学科学院肿瘤医院城市癌症早诊早治项目办公室
    3. 250117 济南,山东省肿瘤医院肿瘤防治办公室
    4. 100021 北京,中国医学科学院肿瘤医院乳腺外科
  • 收稿日期:2016-08-30 出版日期:2018-12-01
  • 通信作者: 石菊芳, 刘玉琴
  • 基金资助:
    国家自然科学基金青年科学基金资助项目(81402740)

Population-based prognostic parameters of breast cancer

Lili Chen1, Jufang Shi2(), Yuqin Liu1()   

  • Received:2016-08-30 Published:2018-12-01
  • Corresponding author: Jufang Shi, Yuqin Liu
引用本文:

陈莉莉, 石菊芳, 刘玉琴, 岳馨培, 王乐, 马恒敏, 黄慧瑶, 王仲照, 代敏. 基于人群的乳腺癌预后参数研究现状[J/OL]. 中华乳腺病杂志(电子版), 2018, 12(06): 370-372.

Lili Chen, Jufang Shi, Yuqin Liu. Population-based prognostic parameters of breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(06): 370-372.

乳腺癌是女性最常见的恶性肿瘤,已成为危及全世界妇女健康的第一位恶性肿瘤,严重影响女性的健康。乳腺癌生存率与临床分期、肿瘤直径、病理分级、治疗方式等密切相关。笔者回顾了基于人群的乳腺癌预后研究,大部分研究来自欧美发达国家,目前以人群为基础的不同肿瘤分期乳腺癌患者生存率数据在中国尚有限。女性乳腺癌患者1、5、10年相对生存率中位数及范围依次为95.0%(58.9%~99.0%)、80.4%(45.1%~93.0%)和73.4%(56.8%~84.4%)。细化乳腺癌患者TNM分期和I~Ⅳ临床分期生存率的文献有限,但依然提示早期乳腺癌如T1N0M0或临床分期Ⅰ期患者,其5年生存率接近100%;而晚期乳腺癌患者5年生存率仅约为20%。不同肿瘤直径亚组间5年中位生存率差别最大(42.4%),其次为病理分级(24.7%)、治疗方式(11.9%)和组织学类型(5.1%)。总之,乳腺癌患者总体预后较好,尤其是早期患者,但细化的临床分期证据有限,有待进一步研究。同时,笔者通过深入比较相关因素与乳腺癌生存率的关系,评价乳腺癌预后参数及其影响因素,为后期构建乳腺癌预后模型提供数据支持,也为提高临床诊疗水平提供帮助。

[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLO-BOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-386.
[2]
赫捷,陈万青. 2012中国肿瘤登记年报 [M].北京:军事医学科技出版社,2012.
[3]
Campbell ID, Scott N, Seneviratne S, et al. Breast cancer survival in New Zealand women [J]. ANZ J Surg, 2015, 85(7/8):546-552.
[4]
Barchielli A, Paci E, Balzi D, et al. Population-based breast cancer survival. Mammographic screening activities in central Italy [J]. Cancer, 1994, 74(12): 3126-3134.
[5]
Gajalakshmi CK, Shanta V, Swaminathan R, et al. A population-based survival study on female breast cancer in Madras, India [J]. Br J Cancer, 1997, 75(5): 771-775.
[6]
Larranaga N, Sarasqueta C, Martinez-Camblor P, et al. Female breast cancer in Gipuzkoa: prognostic factors and survival [J]. Clin Transl Oncol, 2009,11(2): 96-102.
[7]
Nelson RA, Guye ML, Luu T, et al. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis [J]. Ann Surg Oncol, 2015, 22(1):24-31.
[8]
Zhu J, Chen JG, Chen YS, et al. Female breast cancer survival in Qidong, China, 1972-2011: a population-based study [J]. BMC Cancer, 2014, 14(1): 318.
[9]
Walters S, Maringe C, Butler J,et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study [J]. Br J Cancer, 2013, 108(5): 1195-1208.
[10]
Dabakuyo TS, Bonnetain F, Roignot P, et al. Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survival[J]. Ann Oncol, 2008, 19(2): 276-283.
[11]
Baburin A, Aareleid T, Padrik P, et al. Time trends in population-based breast cancer survival in Estonia: analysis by age and stage[J]. Acta Oncol, 2014, 53(2): 226-234.
[12]
Abdullah NA, Wan Mahiyuddin WR, Muhammad NA, et al. Survival rate of breast cancer patients in Malaysia: a population-based study [J]. Asian Pac J Cancer Prev,2013,14(8):4591-4594.
[13]
Christensen LH, Engholm G, Ceberg J, et al. Can the survival difference between breast cancer patients in Denmark and Sweden 1989 and 1994 be explained by patho-anatomical variables?--a population-based study [J]. Eur J Cancer, 2004, 40(8): 1233-1243.
[14]
Clayforth C, Fritschi L, McEvoy S, et al. Five-year survival from breast cancer in Western Australia over a decade[J]. Breast, 2007, 16(4): 375-381.
[15]
Elkin EB, Hudis C, Begg CB, et al. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999[J]. Cancer, 2005, 104(6): 1149-1157.
[16]
Holleczek B, Brenner H. Provision of breast cancer care and survival in Germany - results from a population-based high resolution study from Saarland [J]. BMC Cancer, 2014,14: 757.
[17]
Jensena AR, Ewertz M, Cold S, et al. Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark [J]. Eur J Cancer, 2003, 39(12): 1783-1793.
[18]
Pal S, Lüchtenborg M, Davies EA, et al. The treatment and survival of patients with triple negative breast cancer in a London population [J]. Springerplus,2014,3:553.
[19]
Taylor R, Coates M. Breast cancer five-year survival in New South Wales women, 1972 to 1991[J]. Aust N Z J Public Health, 1997, 21(2): 199-205.
[20]
Tejler G, Norberg B, Dufmats M, et al. Survival after treatment for breast cancer in a geographically defined population [J]. Br J Surg, 2004, 91(10): 1307-1312.
[21]
Wishart GC, Greenberg DC, Chou P, et al. Treatment and survival in breast cancer in the Eastern Region of England [J]. Ann Oncol, 2010, 21(2): 291-296.
[22]
Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe [J]. Int J Cancer, 2003, 106(3): 416-422.
[23]
Ali AM, Greenberg D, Wishart G, et al. Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England [J]. Br J Cancer, 2011, 104(4): 564-570.
[24]
Holleczek B, Arndt V, Stegmaier C, et al. Trends in breast cancer survival in Germany from 1976 to 2008--a period analysis by age and stage [J]. Cancer Epidemiol, 2011, 35(5): 399-406.
[25]
Holleczek B, Brenner H. Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany [J]. BMC Cancer, 2012(12): 317.
[26]
Allemani C, Sant M, Weir HK, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study [J]. Int J Cancer, 2013, 132(5): 1170-1181.
[27]
Ugnat AM, Xie L, Morriss J, et al. Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment[J]. Br J Cancer, 2004, 90(6): 1138-1143.
[28]
Zeng H, Zheng R, GuoY, et al. Cancer survival in China, 2003-2005: A population-based study [J]. Int J Cancer, 2015,136(8):1921-1930.
[29]
Woods LM, Rachet B, Cooper N, et al. Predicted trends in long-term breast cancer survival in England and Wales [J]. Br J Cancer, 2007, 96(7): 1135-1138.
[30]
Halmin M, Bellocco R, Lagerlund M, et al. Long-term inequalities in breast cancer survival--a ten year follow-up study of patients managed within a National Health Care System (Sweden) [J]. Acta Oncol, 2008, 47(2): 216-224.
[31]
Han W, Kang SY. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer [J]. Breast Cancer Res Treat, 2010, 119(1):193-200.
[32]
Kocic B, Filipovic S, Vrbic V,et a1.Breast cancer in women under 40 years of age [J]. J BUON,2011,16(4):635-639.
[33]
Moller H, Sandin F, Bray F, et al. Breast cancer survival in England, Norway and Sweden: a population-based comparisone [J]. Int J Cancer, 2010, 127(11): 2630-2638.
[34]
Spilsbury K, Semmens JB, Saunders CM, et al. Long-term survival outcones following breast cancer surgery in Western Australia [J]. ANZ J Surg, 2005, 75(8): 625-630.
[35]
Bertheau P, Steinberg SM, Cowan K, et al. Breast cancer in young women:clinicopathologic correlation[J].Semin Diagn Pathol,1999,16(3):2482-2485.
[36]
Nechuta S. Comorbidities and breast cancer survival: a report from the Shanghai breast cancer survival study [J]. Breast Cancer Res Treat, 2013, 139(1): 227-235.
[37]
Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival [J]. Cancer, 1989, 63(5): 976-981.
[38]
中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版) [J]. 中国癌症杂志,2017, 27(9): 695-759.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[4] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[8] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[9] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[10] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[11] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要